Press Releases
[Sep 2010] PolyTherics moves lead candidate into development and manufacturing with DSM BioSolutions
DSM BioSolutions (“DSM”), DSM’s microbial fermentation CMO business unit and PolyTherics Limited ("PolyTherics"), an innovator in precision engineering of proteins, today announced that they have entered into an agreement for the process development and manufacture of PolyTherics’ lead biobetter product, HiPEG™ IFN α-2a.
[Aug 2010] PolyTherics’ growth spurs move to larger premises
PolyTherics Limited ("PolyTherics"), an innovator in precision engineering of proteins and peptides, today announced it has moved to larger premises to accommodate a growing team of scientists developing biobetters and novel proteins and peptides, both in-house and in partnership with pharmaceutical and biotechnology companies.
[Jun 2010] PolyTherics to Receive Knowledge Transfer Partnership Programme Funding
PolyTherics Limited ("PolyTherics"), innovators in precision engineering of proteins, today announced that the Technology Strategy Board (TSB) had offered The School of Pharmacy, University of London, a Knowledge Transfer Partnership (“KTP”) grant that will be used to part-fund work being undertaken in collaboration with PolyTherics.
[Jun 2010] PolyTherics appoints new Chairman
PolyTherics Limited (“PolyTherics”), the biopharmaceutical company dedicated to precision engineering of proteins and peptides to improve their pharmacokinetic properties, is pleased to announce that Dr Ken Cunningham has been appointed Chairman. Dr Mike Hayes, the current Non-Executive Chairman, will continue as a Non-Executive Director.
[Apr 2010] PolyTherics receives a Technology Strategy Board grant to develop novel fusion proteins
PolyTherics Limited, innovators in precision engineering of proteins, today announced that it has started work on a Technology Strategy Board ("TSB") funded project to produce fusion proteins using its chemical linker technologies. PolyTherics will chemically fuse different but complementary proteins using its proprietary polyethylene glycol (PEG) linkers.
[Mar 2010] Zealand Pharma and PolyTherics Enter Collaboration Agreement for Novel Optimised Biopharmaceuticals
Zealand Pharma, the Danish biopharmaceutical company recognised as a leader in the discovery and development of peptide-based drugs and PolyTherics Limited, innovators in precision engineering of proteins to improve their pharmacokinetic properties, today announced a research collaboration.
[Feb 2010] PolyTherics Raises £3 million to Commercialise PEGylation Technologies
PolyTherics Limited, innovators in precision engineering of proteins as biotherapeutic products, is pleased to announce the completion of an investment round of £3.0 million in the company. The investment round was led by Imperial Innovations Group plc, the technology investment and commercialisation company (AIM: IVO), and included Longbow Capital and The Capital Fund. This investment follows on from a £2.3 million financing backed by the same syndicate in June 2007.
[Jan 2010] Celtic Pharma Holdings and PolyTherics announce investment into novel biopharmaceutical programme
Celtic Pharma Holdings Advisors LLP, the advisor to Celtic Pharma Holdings II LP, together with PolyTherics Limited, innovators in precision engineering of proteins to improve their pharmacokinetic properties, today announce an investment into a research programme to develop a novel biopharmaceutical molecule.
